CLINICAL TRIALS PROFILE FOR OXERVATE
✉ Email this page to a colleague
All Clinical Trials for OXERVATE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04485546 ↗ | Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis | Recruiting | Dompé US | Phase 4 | 2020-09-09 | This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK). |
NCT04485546 ↗ | Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis | Recruiting | Dompé Farmaceutici S.p.A | Phase 4 | 2020-09-09 | This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK). |
NCT05133180 ↗ | Study to Evaluate Safety and Efficacy of Oxervate® Ophthalmic Solution vs Vehicle in Severe Sjogren's Dry Eye Disease | Not yet recruiting | Dompé Farmaceutici S.p.A | Phase 3 | 2021-11-30 | The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients with severe Sjogren's dry eye disease. |
NCT05136170 ↗ | Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) 20 mcg/mL vs Vehicle, in Patients With Sjogren's Dry Eye | Not yet recruiting | Dompé Farmaceutici S.p.A | Phase 3 | 2021-12-01 | The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients with severe Sjogren's dry eye disease (DED) who are under chronic treatment with topical Cyclosporine A (CsA). |
NCT05700864 ↗ | NGF Treatment for Patients With Neuropathic Corneal Pain | Withdrawn | Dompé Farmaceutici S.p.A | Phase 1 | 2022-11-01 | This prospective, single center, interventional, open-label, single arm, non-randomized trial seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating the signs and symptoms of neuropathic corneal pain (NCP). The study aims to enroll 28 subjects with NCP. All patients will be evaluated for clinical symptoms and signs of NCP, corneal staining and nerve regeneration (by IVCM) at Baseline (Visit 2) through the end of study (16 weeks post treatment). |
NCT05700864 ↗ | NGF Treatment for Patients With Neuropathic Corneal Pain | Withdrawn | Tufts Medical Center | Phase 1 | 2022-11-01 | This prospective, single center, interventional, open-label, single arm, non-randomized trial seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating the signs and symptoms of neuropathic corneal pain (NCP). The study aims to enroll 28 subjects with NCP. All patients will be evaluated for clinical symptoms and signs of NCP, corneal staining and nerve regeneration (by IVCM) at Baseline (Visit 2) through the end of study (16 weeks post treatment). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OXERVATE
Condition Name
Clinical Trial Locations for OXERVATE
Trials by Country
Clinical Trial Progress for OXERVATE
Clinical Trial Phase
Clinical Trial Sponsors for OXERVATE
Sponsor Name